Cas:500285-04-1 (2-ethyl-7H-purin-6-yl)thiourea manufacturer & supplier

Chemical Name:(2-ethyl-7H-purin-6-yl)thiourea

CAS.NO:500285-04-1

Synonyms:(2-ethyl-7H-purin-6-yl)thiourea

Molecular Formula:C₈H₁₀N₆S

Molecular Weight:222.27000

HS Code:

Physical and Chemical Properties:

Melting point:N/A

Boiling point:N/A

Density:N/A

Index of Refraction:

PSA:129.14000

Exact Mass:222.06900

LogP:1.36450

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like (2-ethyl-7H-purin-6-yl)thiourea chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,(2-ethyl-7H-purin-6-yl)thiourea physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,(2-ethyl-7H-purin-6-yl)thiourea Use and application,(2-ethyl-7H-purin-6-yl)thiourea technical grade,usp/ep/jp grade.

Related News: In addition, with the increase of environmental protection pressure, nearly one hundred Beijing pharmaceutical companies have gathered in the Bohai Bay, and the raw material drug base in northern China has taken shape. (2-ethyl-7H-purin-6-yl)thiourea manufacturer If the government does not close the border and heed their other demands by 9 p.m., union members handling emergency services would also strike, the union said. (2-ethyl-7H-purin-6-yl)thiourea supplier The entire set of results “strongly support” the Darzalex-Rd combo as a new standard of care for newly diagnosed, transplant-ineligible multiple myeloma patients, Thierry Facon, M.D., an investigator of the MAIA trial, said in a statement. (2-ethyl-7H-purin-6-yl)thiourea vendor Thank you for being open” about the diagnosis, NBC’s chief foreign affairs correspondent and anchor Andrea Mitchell wrote to Amanpour on Twitter. “It is so important and typical of how strong and brave you’ve always been. Courage and honesty is your trademark. You will beat this too. (2-ethyl-7H-purin-6-yl)thiourea factory The entire set of results “strongly support” the Darzalex-Rd combo as a new standard of care for newly diagnosed, transplant-ineligible multiple myeloma patients, Thierry Facon, M.D., an investigator of the MAIA trial, said in a statement.